Spectrum begins Phase II trial of Poziotinib to treat breast cancer

US-based Spectrum Pharmaceuticals has begun a Phase II clinical trial of its new pan-HER inhibitor, Poziotinib, for patients with HER2-positive metastatic breast cancer.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news